These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2. van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932 [TBL] [Abstract][Full Text] [Related]
3. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575 [TBL] [Abstract][Full Text] [Related]
4. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666 [TBL] [Abstract][Full Text] [Related]
6. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507. Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760 [TBL] [Abstract][Full Text] [Related]
9. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas. Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098 [TBL] [Abstract][Full Text] [Related]
10. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350 [TBL] [Abstract][Full Text] [Related]
11. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
12. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments. Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907 [TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420 [TBL] [Abstract][Full Text] [Related]
15. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358 [TBL] [Abstract][Full Text] [Related]
16. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model. Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646 [TBL] [Abstract][Full Text] [Related]
17. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer. de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using Shi D; Zhang Y; Xu Z; Si Z; Cheng Y; Cheng D; Liu G Mol Imaging; 2022; 2022():3748315. PubMed ID: 35903247 [TBL] [Abstract][Full Text] [Related]
19. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related]